Skip to main content
. 2022 Apr 19;75(7):1245–1254. doi: 10.1093/cid/ciac291

Table 3.

Priorities for Data Requirements Describing Burden of Disease Across Vaccine Development and Evaluation Objectives for Immune-Mediated Sequalae of Group A Streptococcus

Objective
Clinical Endpoint Advocacy Regulatory/Licensure Policy and Post-Licensure Evaluation Financing
ARF
  • Age-specific incidence and changes over time

HICs:
  • Unlikely to be a driver except in First Nation sub-populations

  • Not critical as initial efficacy needs to be demonstrated for pharyngitis and impetigo but need to plan for post-licensure evaluation

HICs:
  • Relevant for First Nation sub-populations

LMICs:
  • Determination of pathway for evaluating impact on severe disease outcomes from early acute infection

  • Age-specific incidence and changes over time.

  • Attack rates from acute diseases to ARF (difficult to obtain)

HICs:
  • Relevant for First Nation sub-populations

LMICs:
  • Data on socioeconomic indicators

  • Progression from acute infection

  • Retrospective economic (cost of illness) data targeted to hospitalizations and treatment

HICs:
  • Relevant for First Nation sub-populations

RHD
  • Prevalence in certain at-risk groups

HICs:
  • Relevant for First Nation sub-populations

LMICs:
  • Severity of RHD

  • Not critical as initial efficacy needs to be demonstrated for pharyngitis and impetigo but need to plan for post-licensure evaluation

LMICs:
  • Determination of pathway for evaluating impact on severe disease outcomes from early acute infection

  • Age-specific prevalence and temporal changes

  • Need to understand progression from acute infection (pharyngitis) to estimate long-term reduction from pharyngitis prevention

HICs:
  • Relevant for First Nation sub-populations

LMICs:
  • Data on socioeconomic indicators

  • Progression from acute infection

  • Retrospective economic (cost of illness) data targeted to hospitalizations, treatment, and mortality

HICs:
  • Relevant for First Nation sub-populations

APSGN
  • Not a critical driver for advocacy

  • Not required as efficacy needs to be demonstrated for pharyngitis

  • Plan for post-licensure evaluation of impact

  • Retrospective economic (cost of illness) data targeted to hospitalizations and treatment

LMICs:
  • Potential impact on long-term chronic renal disease

Abbreviations: APSGN, acute post-streptococcal glomerulonephritis; ARF, acute rheumatic fever; HIC, high-income country; LMIC, low- and middle-income country; RHD, rheumatic heart disease.